Type 2 Diabetes Therapeutics in Asia-Pacific Markets to 2020 - Increasing Uptake of Novel Drug Classes to Drive Market Growth
The new report discusses the type 2 diabetes therapeutics market in Asia Pacific. The report focuses on the four major countries in Asia Pacific – China, India, Australia, Japan – to provide an accurate snapshot of the Asia Pacific market for type 2 diabetes therapeutics.
The new report, titled ‘ Type 2 Diabetes Therapeutics in Asia-Pacific Markets to 2020 - Increasing Uptake of Novel Drug Classes to Drive Market Growth’, is authored by GBI Research and presents detailed historical statistics regarding the Asia Pacific type 2 diabetes therapeutics market. It then examines the trends determining the present dynamics of the market and projects future market forecasts based on the same.
Browse Full Report
with TOC : http://www.mrrse.com/type-2-diabetes-therapeutics-in-asia-pacific-markets
The report predicts that, aided by the growing prevalence of
type 2 diabetes in India and China, the Asia Pacific type 2 diabetes
therapeutics market is set to grow to a value of US$10.5 billion by 2020, at a
CAGR of 7.1% from its 2013 market value of US$6.5 billion.
The report segments the Asia Pacific type 2 diabetes
therapeutics market by product type and geography. Both currently marketed and
pipeline therapeutics are profiled in the report. DPP-4 inhibitors such as
Januvia and Tradjenta, GLP-1 agonists such as Lyxumia and Victoza,
sulfonylureas such as Gliclazide and Glimepiride, thiazolidinediones such as
Actos, long-acting insulins such as Levemir and Lantus, and SGLT inhibitors
such as Forxiga and Invokana are the major product categories within the Asia
Pacific type 2 diabetes therapeutics market.
The report presents in-depth data about the major national
markets in the type 2 diabetes therapeutics market in Asia Pacific: China,
India, Australia, and Japan.
The report presentshistorical data charting the
progress of the market in each country and forecasts for the market’s expected
growth from 2013 to 2020. Data regarding revenue and volume sales achieved by
each of the main product types of type 2 diabetes therapeutics in each national
market is presented in the report, for a comprehensive understanding of the
market dynamics in each major market.
Pipeline products in the Asia Pacific type 2 diabetes
therapeutics market are studied according to molecule type, phase distribution,
program type, molecular target, and mechanism of action. The report explains
the effect of the growing government approval for new classes of drugs such as
SGLT inhibitors and GLP-1 agonists as the prime growth drivers for the Asia
Pacific type 2 diabetes therapeutics market.
Send An Enquiry: http://www.mrrse.com/enquiry/130
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Symptoms 8
2.2 Etiology 8
2.3 Pathophysiology 9
2.4 Diagnosis 10
2.5 Epidemiology 12
2.6 Prognosis 13
2.7 Co-Morbidities and Complications 13
2.8 Treatment and Management 14
2.8.1 The Role of Insulin in Type 2 Diabetes 17
2.8.2 Non-Insulin Diabetic Drugs 18
2.8.3 Other Drugs 20
3 Marketed Products 21
3.1 Metformin 21
3.2 DPP-4 Inhibitors 22
3.2.1 Januvia (sitagliptin)/Janumet (sitagliptin and metformin),
Merck 22
3.2.2 Tradjenta (linagliptin) – Boehringer Ingelheim 23
3.2.3 Onglyza (saxagliptin) – Bristol-Myers Squibb and
AstraZeneca 24
3.2.4 Nesina (alogliptin) – Takeda 24
3.2.5 Galvus (vildagliptin) – Novartis 25
3.2.6 Tenelia (teneligliptin) – Daiichi Sankyo and Mitsubishi
Tanabe 26
3.3 GLP-1 Agonists 27
3.3.1 Byetta and Bydureon (exenatide) – Bristol-Myers Squibb 27
3.3.2 Victoza (liraglutide) – Novo Nordisk 27
3.3.3 Lyxumia (lixisenatide) – Sanofi 28
3.4 Sulfonylureas 29
3.4.1 Glimepiride 29
3.4.2 Gliclazide 30
3.5 Thiazolidinediones 30
3.5.1 Actos (pioglitazone) – Takeda Pharmaceuticals 30
3.6 Long-Acting Insulins 31
3.6.1 Lantus (insulin glargine) – Sanofi 31
3.6.2 Levemir (insulin detemir) – Novo Nordisk 32
3.7 SGLT Inhibitors 33
3.7.1 Forxiga (dapagliflozin) – Bristol-Myers Squibb 33
3.7.2 Invokana (canagliflozin) – Janssen 33
3.8 Comparative Efficacy and Safety 34
4 Type 2 Diabetes
Market to 2020 – Pipeline Products 36
4.1 Overall Pipeline 36
4.2 Pipeline Analysis by Molecule Type 37
4.3 Pipeline Analysis by Mechanism of Action 38
4.4 Clinical Trials 42
4.4.1 Failure Rate 42
4.4.2 Patient Enrollment and Clinical Trial Size 46
4.4.3 Duration 47
4.5 Promising Drug Candidates in the Pipeline 48
4.5.1 LY-2189265 (dulaglutide) – Eli Lilly 48
4.5.2 Albiglutide – GlaxoSmithKline 49
4.5.3 Ipragliflozin – Astellas Pharma 50
4.5.4 Semaglutide – Novo Nordisk 50
5 Market Forecast to
2020 51
5.1 Geographical Markets 51
5.1.1 Asia-Pacific Market 51
5.1.2 China 53
5.1.3 India 55
5.1.4 Japan 57
5.1.5 Australia 59
5.2 Drivers and Barriers 61
5.2.1 Drivers 61
5.2.2 Barriers 61
6 Deals and Strategic
Consolidations 62
6.1 Major Licensing Deals 63
6.1.1 Viking Therapeutics Enters into Licensing Agreement with
Ligand Pharma 64
6.1.2 Zosano Pharma Enters into Licensing Agreement with Novo
Nordisk 64
6.1.3 Sirona Biochem Enters into Licensing Agreement with
Wanbang Biopharma for SGLT2 Inhibitor 65
6.1.4 Depomed Expands Licensing Agreement with Merck for
Metformin Patents 65
6.1.5 Chugai Pharma Enters into Licensing Agreement with Kowa
and Sanofi for SGLT2 Inhibitor CSG452 65
6.2 Major Co-development Deals 65
6.2.1 Yabao Pharma Enters into Co-Development Agreement with Eli
Lilly for LY2608204 66
6.2.2 AstraZeneca Enters into Co-development Agreement with
Bristol-Myers Squibb 66
6.2.3 Isis Pharmaceuticals Enters into a Collaboration Agreement
with Janssen Pharmaceuticals 67
6.2.4 Merck Enters into Co-Development Agreement with Pfizer for
Ertugliflozin 67
7 Appendix 68
7.1 All Pipeline Drugs by Phase 68
7.1.1 Discovery 68
7.1.2 IND/CTA-Filed 71
7.1.3 Preclinical 72
7.1.4 Phase I 82
7.1.5 Phase II 85
7.1.6 Phase III 88
7.1.7 Pre-registration 90
7.1.8 Undisclosed 91
7.2 Market Forecasts to 2019 92
7.2.1 Global 92
7.2.2 China 93
7.2.3 India 93
7.2.4 Japan 94
7.2.5 Australia 94
7.3 Market Definitions 95
7.4 Abbreviations 95
7.5 References 97
7.6 Research Methodology 103
7.6.1 Coverage 103
7.6.2 Secondary Research 103
7.6.3 Primary Research 103
7.6.4 Therapeutic Landscape 104
7.6.5 Geographical Landscape 106
7.6.6 Pipeline Analysis 107
7.7 Expert Panel Validation 107
7.8 Contact Us 107
7.9 Disclaimer 107
About Us:
Market Research Reports Search Engine (MRRSE) is an
industry-leading database of market intelligence reports. Headquartered in New
York, U.S., MRRSE is driven by a stellar team of research experts and advisors
trained to offer objective advice. Our sophisticated search algorithm returns
results based on the report title, geographical region, publisher, or other
keywords.
MRRSE partners exclusively with leading global publishers to
provide clients single-point access to top-of-the-line market research. MRRSE’s
repository is updated every day to keep its clients ahead of the next new trend
in market research, be it competitive intelligence, product or service trends
or strategic consulting.
Contact
State Tower
90, State Street
Suite 700
Albany, NY - 12207
United States
Telephone:
+1-518-618-1030
Email: sales@mrrse.com
Website: http://www.mrrse.com/
Comments
Post a Comment